Home   Business   Life Science

Subscribe Now

Life Science




Mission Therapeutics earns $20m milestone payment from AbbVie in Alzheimer’s and Parkinson’s collaboration

Mission Therapeutics earns $20m milestone payment from AbbVie in Alzheimer’s and Parkinson’s collaboration

Mission Therapeutics earns $20m milestone payment from AbbVie in Alzheimer’s and Parkinson’s collaboration

Two targets have been identified.

4

Maggot enzyme in wound-cleaning product Aurase powers Cambridge biotech start-up SolasCure to £15m Series A raise

Maggot enzyme in wound-cleaning product Aurase powers Cambridge biotech start-up SolasCure to £15m Series A raise

Maggot enzyme in wound-cleaning product Aurase powers Cambridge biotech start-up SolasCure to £15m Series A raise

Industry veterans have backed the company.


Stemnovate raises more than £1m to expand commercialisation of its drug discovery and diagnostic technology

Stemnovate raises more than £1m to expand commercialisation of its drug discovery and diagnostic technology

Stemnovate raises more than £1m to expand commercialisation of its drug discovery and diagnostic technology

The company is already with pharma and universities.


Cambridge neuroscience specialist NRG Therapeutics secures $500,000 Parkinson’s research grant

Cambridge neuroscience specialist NRG Therapeutics secures $500,000 Parkinson’s research grant

Cambridge neuroscience specialist NRG Therapeutics secures $500,000 Parkinson’s research grant

It is plotting a Series A funding round.

3

Mestag Therapeutics extends seed round to $45m

Mestag Therapeutics extends seed round to $45m

Mestag Therapeutics extends seed round to $45m

The immuno-oncology and inflammatory disease specialist is targeting activated fibroblast populations.


‘A revolution for life sciences’ - DeepMind and EMBL-EBI release database of human protein structures

‘A revolution for life sciences’ - DeepMind and EMBL-EBI release database of human protein structures

‘A revolution for life sciences’ - DeepMind and EMBL-EBI release database of human protein structures

It will lead to new treatments for disease.


Artios secures £110m to progress its cancer-killing DDR platform

Artios secures £110m to progress its cancer-killing DDR platform

Artios secures £110m to progress its cancer-killing DDR platform

The oversubscribed round was co-led by Omega Funds and TCG X.


Biofidelity confirms scientific advisory board as it heads towards launch of ASPYRE-Lung diagnostic test

Biofidelity confirms scientific advisory board as it heads towards launch of ASPYRE-Lung diagnostic test

Biofidelity confirms scientific advisory board as it heads towards launch of ASPYRE-Lung diagnostic test

It includes pharma leaders and patient advocates.


University of Cambridge Enterprize Zone draws up roadmap for strengthening positioning as global healthtech leader

University of Cambridge Enterprize Zone draws up roadmap for strengthening positioning as global healthtech leader

University of Cambridge Enterprize Zone draws up roadmap for strengthening positioning as global healthtech leader

Connect: Health Tech suggest how cultural, financial and geographical challenges can be overcome.


OKRA.ai to collaborate with AWS for Health initiative

OKRA.ai to collaborate with AWS for Health initiative

OKRA.ai to collaborate with AWS for Health initiative

It is designed to help life science companies roll out solutions more quickly.


AstraZeneca completes $39bn acquisition of Alexion Pharmaceuticals

AstraZeneca completes $39bn acquisition of Alexion Pharmaceuticals

AstraZeneca completes $39bn acquisition of Alexion Pharmaceuticals

It brings the company greater immunology and rare disease expertise.


Award for Cambridge researchers who showed plasma viscosity can predict progression of Covid-19

Award for Cambridge researchers who showed plasma viscosity can predict progression of Covid-19

Award for Cambridge researchers who showed plasma viscosity can predict progression of Covid-19

Daniel Gleghorn and colleagues at Cambridge University Hospitals won the award from Benson Viscometers.


$45m upfront fee for Bicycle Therapeutics under deal with Ionis Pharmaceuticals

$45m upfront fee for Bicycle Therapeutics under deal with Ionis Pharmaceuticals

$45m upfront fee for Bicycle Therapeutics under deal with Ionis Pharmaceuticals

The Babraham Research Campus company will develop tissue-targeted oligonucleotide therapeutics.


Apollo Therapeutics’ $145m financing follows collaboration at University of Cambridge, Imperial College London and UCL

Apollo Therapeutics’ $145m financing follows collaboration at University of Cambridge, Imperial College London and UCL

Apollo Therapeutics’ $145m financing follows collaboration at University of Cambridge, Imperial College London and UCL

The company was created to speed up the development of therapeutics.


This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More